Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)

PHASE4RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

January 15, 2025

Study Completion Date

February 10, 2025

Conditions
Type 2 Diabetes PatientsOverweight and ObesityHyperglycaemia (Diabetic)
Interventions
DRUG

Liraglutide

Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.

DRUG

insulin glargine

Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.

Trial Locations (1)

361003

RECRUITING

The first afilliated hospital of Xiamen university, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER